Shilpa Medicare reports strong FY25 growth and strategic advancements

Shilpa Medicare Limited reported a robust financial performance for FY25, with consolidated operating revenue increasing by 12% to ₹1,28,641.40 Lakhs from ₹1,15,160.30 Lakhs in FY24. Net profit surged by 158% to ₹7,599.22 Lakhs, up from ₹2,950.36 Lakhs in the previous year. This growth was primarily driven by strong contributions from its Formulations and Biologics businesses, which grew by 37% and 115% respectively. The company's EBITDA also saw a significant year-on-year increase of 35% to ₹34,021 Lakhs.

The company made significant strategic advancements, including successfully raising ₹500 Crores through a Qualified Institutional Placement (QIP) of equity shares, which has been fully utilized for the stated objectives. In its API division, Shilpa Medicare expanded capacities for key products and secured European CEPs for two Peptide products. The Formulations division launched new products, including the first generic Nilotinib in the EU, and achieved approval for the first oral fluid formulation, Imatinib, through its JV company.

Looking ahead, Shilpa Medicare remains committed to driving sustainable growth through continuous R&D investment, technological advancement, and strategic partnerships. The company plans further expansion in high-growth therapeutic segments and enhanced CDMO capabilities, with a focus on both domestic and international markets. The 38th Annual General Meeting is scheduled for Tuesday, September 23, 2025, at 11:00 AM (IST) via Video Conferencing.